Literature DB >> 24984921

MELD exceptions for portopulmonary hypertension: current policy and future implementation.

D S Goldberg1, S Batra, S Sahay, S M Kawut, M B Fallon.   

Abstract

Since 2006, waitlist candidates with portopulmonary hypertension (POPH) have been eligible for standardized Model for End-Stage Liver Disease (MELD) exception points. However, there are no data evaluating the current POPH exception policy and its implementation. We used Organ Procurement and Transplantation Network (OPTN) data to compare outcomes of patients with approved POPH MELD exceptions from 2006 to 2012 to all nonexception waitlist candidates during this period. Since 2006, 155 waitlist candidates had approved POPH MELD exceptions, with only 73 (47.1%) meeting the formal OPTN exception criteria. Furthermore, over one-third of those with approved POPH exceptions either did not fulfill hemodynamic criteria consistent with POPH or had missing data, with 80% of such patients receiving a transplant based on receiving exception points. In multivariable multistate survival models, waitlist candidates with POPH MELD exceptions had an increased risk of death compared to nonexception waitlist candidates, regardless of whether they did (hazard ratio [HR]: 2.46, 95% confidence interval [CI]: 1.73-3.52; n = 100) or did not (HR: 1.60, 95% CI: 1.04-2.47; n = 55) have hemodynamic criteria consistent with POPH. These data highlight the need for OPTN/UNOS to reconsider not only the policy for POPH MELD exceptions, but also the process by which such points are awarded. © Copyright 2014 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Keywords:  Clinical research; United Network for Organ Sharing (UNOS); editorial; organ allocation; organ procurement and allocation; personal viewpoint; practice

Mesh:

Year:  2014        PMID: 24984921      PMCID: PMC4340069          DOI: 10.1111/ajt.12783

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  21 in total

1.  Treatment with sildenafil and treprostinil allows successful liver transplantation of patients with moderate to severe portopulmonary hypertension.

Authors:  Trina J Hollatz; Alexandru Musat; Susanne Westphal; Catherine Decker; Anthony M D'Alessandro; Jon Keevil; Li Zhanhai; James R Runo
Journal:  Liver Transpl       Date:  2012-06       Impact factor: 5.799

2.  Increasing disparity in waitlist mortality rates with increased model for end-stage liver disease scores for candidates with hepatocellular carcinoma versus candidates without hepatocellular carcinoma.

Authors:  David Goldberg; Benjamin French; Peter Abt; Sandy Feng; Andrew M Cameron
Journal:  Liver Transpl       Date:  2012-04       Impact factor: 5.799

3.  Waitlist priority for hepatocellular carcinoma beyond milan criteria: a potentially appropriate decision without a structured approach.

Authors:  T Bittermann; B Niu; M A Hoteit; D Goldberg
Journal:  Am J Transplant       Date:  2013-12-04       Impact factor: 8.086

4.  Impact of the hepatopulmonary syndrome MELD exception policy on outcomes of patients after liver transplantation: an analysis of the UNOS database.

Authors:  David S Goldberg; Karen Krok; Sachin Batra; James F Trotter; Steven M Kawut; Michael B Fallon
Journal:  Gastroenterology       Date:  2014-01-08       Impact factor: 22.682

5.  Lack of standardization in exception points for patients with primary sclerosing cholangitis and bacterial cholangitis.

Authors:  D Goldberg; T Bittermann; G Makar
Journal:  Am J Transplant       Date:  2012-02-15       Impact factor: 8.086

6.  Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation.

Authors:  M J Krowka; D J Plevak; J Y Findlay; C B Rosen; R H Wiesner; R A Krom
Journal:  Liver Transpl       Date:  2000-07       Impact factor: 5.799

Review 7.  Pulmonary vascular complications of liver disease.

Authors:  Jason S Fritz; Michael B Fallon; Steven M Kawut
Journal:  Am J Respir Crit Care Med       Date:  2012-11-15       Impact factor: 21.405

8.  Survival in portopulmonary hypertension: Mayo Clinic experience categorized by treatment subgroups.

Authors:  K L Swanson; R H Wiesner; S L Nyberg; C B Rosen; M J Krowka
Journal:  Am J Transplant       Date:  2008-09-08       Impact factor: 8.086

9.  Underreporting of liver transplant waitlist removals due to death or clinical deterioration: results at four major centers.

Authors:  David Goldberg; Benjamin French; James Trotter; Kirti Shetty; Thomas Schiano; K Rajender Reddy; Scott D Halpern
Journal:  Transplantation       Date:  2013-07-27       Impact factor: 4.939

10.  Disparities in liver transplantation before and after introduction of the MELD score.

Authors:  Cynthia A Moylan; Carla W Brady; Jeffrey L Johnson; Alastair D Smith; Janet E Tuttle-Newhall; Andrew J Muir
Journal:  JAMA       Date:  2008-11-26       Impact factor: 56.272

View more
  12 in total

Review 1.  The Art and Science of Diagnosing and Treating Lung and Heart Disease Secondary to Liver Disease.

Authors:  David S Goldberg; Michael B Fallon
Journal:  Clin Gastroenterol Hepatol       Date:  2015-04-28       Impact factor: 11.382

Review 2.  [Hepatocardiac disorders : Interactions between two organ systems].

Authors:  T Horvatits; A Drolz; K Rutter; K Roedl; S Kluge; V Fuhrmann
Journal:  Med Klin Intensivmed Notfmed       Date:  2015-06-13       Impact factor: 0.840

Review 3.  Hepatopulmonary Syndrome and Portopulmonary Hypertension: The Pulmonary Vascular Enigmas of Liver Disease.

Authors:  Michael J Krowka
Journal:  Clin Liver Dis (Hoboken)       Date:  2020-03-02

Review 4.  The Intersection of Pulmonary Hypertension and Solid Organ Transplantation.

Authors:  Adaani E Frost
Journal:  Methodist Debakey Cardiovasc J       Date:  2016 Oct-Dec

5.  Predictors of Waitlist Mortality in Portopulmonary Hypertension.

Authors:  Michael J Krowka; Richard N Channick; Hilary M DuBrock; David S Goldberg; Norman L Sussman; Sonja D Bartolome; Zakiyah Kadry; Reena J Salgia; David C Mulligan; Walter K Kremers; Steven M Kawut
Journal:  Transplantation       Date:  2017-07       Impact factor: 4.939

Review 6.  Model for end-stage liver disease score and MELD exceptions: 15 years later.

Authors:  Sumeet K Asrani; Patrick S Kamath
Journal:  Hepatol Int       Date:  2015-05-28       Impact factor: 6.047

7.  Hepatopulmonary Syndrome and Portopulmonary Hypertension: Current Status and Implications for Liver Transplantation.

Authors:  Kelley Weinfurtner; Kimberly Forde
Journal:  Curr Hepatol Rep       Date:  2020-07-11

8.  Combined Tricuspid Valve Repair and Orthotopic Liver Transplantation in a Patient With Severe Tricuspid Regurgitation and Pulmonary Hypertension.

Authors:  Nimit Kasliwal; Cheng Yang; Eric J Martinez; Robert F Hebeler; Saravanan Ramamoorthy
Journal:  Cureus       Date:  2022-08-18

Review 9.  Current Approach to the Diagnosis and Management of Portopulmonary Hypertension.

Authors:  Lynn A Fussner; Michael J Krowka
Journal:  Curr Gastroenterol Rep       Date:  2016-06

10.  Pulmonary Vascular Resistance Predicts Mortality and Graft Failure in Transplantation Patients With Portopulmonary Hypertension.

Authors:  Arun Jose; Shimul A Shah; Nadeem Anwar; Courtney R Jones; Kenneth E Sherman; Jean M Elwing
Journal:  Liver Transpl       Date:  2021-06-29       Impact factor: 6.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.